IP Library › Granted Patent US 12,697,390
Granted Patent B2
US 12,697,390 · App. 18/339,305 · Granted Aug 4, 2026

Buffered formulations of exendin (9-39)

Inventors: Xiaofeng Xiong (Santa Clara, CA); Debra Odink (Oakland, CA); Colleen M. Craig (Burlingame, CA); Christine M.N. Smith (San Diego, CA); Tracey L. McLaughlin (Santa Clara, CA)
Assignees: Amylyx Pharmaceuticals, Inc.; The Board of Trustees of the Leland Stanford Junior University
A61K47/12A61K9/0019A61K38/26A61K47/26A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,697,390
App. No.
18/339,305
Granted
Aug 4, 2026
Kind
B2
Abstract

Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.

Claims (21)

1 . A liquid pharmaceutical formulation comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in from about 5.1 to about 6, wherein the exendin (9-39) or the pharmaceutically acceptable salt thereof does not exhibit detectable aggregation in the formulation.

2 . The liquid pharmaceutical formulation of claim 1 , wherein the pH is from about 5.5 to about 6.

3 . The liquid pharmaceutical formulation of claim 1 , wherein the pH is from 5.2 to 6.

4 . The liquid pharmaceutical formulation of claim 1 , wherein the physiologically acceptable buffer comprises an acetate buffer, a citrate buffer, a histidine buffer, a phosphate buffer, or a mixture of two or more thereof.

5 . The liquid pharmaceutical formulation of claim 1 , wherein the physiologically acceptable buffer comprises one or more of sodium acetate, potassium acetate, trisodium citrate, magnesium citrate, potassium citrate, and potassium phosphate.

6 . The liquid pharmaceutical formulation of claim 1 , wherein the tonicity modifier comprises mannitol, dextrose, glycerin, lactose, sucrose, or trehalose.

7 . The liquid pharmaceutical formulation of claim 1 , wherein the liquid pharmaceutical formulation is formulated as a single-use prefilled syringe, as a sterile isotonic solution in a vial or ampule, or as cartridge pen-injector device.

8 . The liquid pharmaceutical formulation of claim 1 , wherein the liquid pharmaceutical formulation further comprises one or more preservatives.

9 . The liquid pharmaceutical formulation of claim 1 , wherein the liquid pharmaceutical formulation further comprises one or more surfactants.

10 . The liquid pharmaceutical formulation of claim 1 , wherein the pharmaceutically acceptable salt of exendin (9-39) comprises sulfate, hydrochloride, phosphate, sulfamate, acetate, trifluoroacetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate, or quinate.

11 . The liquid pharmaceutical formulation of claim 1 , wherein the detectable aggregation in the formulation is determined by whether the formulation remains as a non-gelatinous solution when stored at 50° C. for 18, 24, 36, 48 or 72 hours, and/or by visual or light microscopy inspection of the formulation for aggregation or precipitation when stored at 50° C. for 18, 24, 36, 48 or 72 hours.

12 . A method of treating hyperinsulinemic hypoglycemia in a human subject, comprising administering to the human subject a liquid pharmaceutical formulation comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH of from about 5.1 to about 6, wherein the exendin (9-39) or the pharmaceutically acceptable salt thereof does not exhibit detectable aggregation in the formulation, and wherein liquid pharmaceutical formulation is administered to the human subject in an amount effective to prevent or reduce symptoms of the hyperinsulinemic hypoglycemia.

13 . The method of claim 12 , wherein the liquid pharmaceutical formulation is administered by oral, intravenous, buccal, rectal, parenteral, intraperitoneal, intradermal, intramuscular, subcutaneous, or inhalational administration.

14 . The method of claim 12 , wherein the pH is from about 5.5 to about 6.

15 . The method of claim 12 , wherein the pH is from 5.2 to 6.

16 . The method of claim 12 , wherein the human subject previous had bariatric surgery and/or a related metabolic procedure.

17 . The method of claim 16 , wherein the bariatric surgery and/or the related metabolic procedure comprises Roux-en-Y Gastric Bypass, Vertical Sleeve Gastrectomy, placement of an endosleeve device, duodenal mucosal resurfacing, partial bypass of duodenum, vagal nerve blockade, or pyloroplasty.

18 . The method of claim 12 , wherein the human subject previous had a surgical procedure involving gastrointestinal system.

19 . The method of claim 18 , wherein the surgical procedure comprises esophagectomy, Nissen Fundoplication, or gastrectomy.

20 . The method of claim 12 , wherein the human subject is prediabetic and/or insulin resistant.

21 . The method of claim 12 , wherein treating hyperinsulinemic hypoglycemia reduces the risk, frequency, or severity of hypoglycemic episodes in the human subject.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: EIGER BIOPHARMACEUTICALS, INC.
To: AMYLYX PHARMACEUTICALS, INC.
Reel/Frame 068683/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2024
From: EIGER BIOPHARMACEUTICALS, INC.
To: AMYLYX PHARMACEUTICALS, INC.
Reel/Frame 068283/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2023
From: MCLAUGHLIN, TRACEY L.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 064026/0294 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2023
From: XIONG, XIAOFENG; ODINK, DEBRA; SMITH, CHRISTINE M.N.; CRAIG, COLLEEN M.
To: EIGER BIOPHARMACEUTICALS, INC.
Reel/Frame 064027/0831 →
Continuity (5)
Continuation 17306782 · May 3, 2021
Continuation 16461329 · Nov 21, 2017
Provisional Application 62517065 · Jun 8, 2017
Provisional Application 62424979 · Nov 21, 2016
Related Publication 20240042035A1 · Feb 8, 2024
References Cited (400)
US 5424286A · Eng · 1995 [cited by applicant]
US 6004297A · Steenfeldt-Jensen et al. · 1999 [cited by applicant]
US 6268343B1 · Knudsen et al. · 2001 [cited by applicant]
US 6458924B2 · Knudsen et al. · 2002 [cited by applicant]
US 6469021B1 · Truesdale et al. · 2002 [cited by applicant]
US 6479065B2 · Jaworowicz et al. · 2002 [cited by applicant]
US 6495164B1 · Ramstack et al. · 2002 [cited by applicant]
US 6573291B2 · Gronberg et al. · 2003 [cited by applicant]
US 6667061B2 · Ramstack et al. · 2003 [cited by applicant]
US 6824822B2 · Rickey et al. · 2004 [cited by applicant]
US 6858576B1 · Young et al. · 2005 [cited by applicant]
US 6872700B1 · Young et al. · 2005 [cited by applicant]
US 6902744B1 · Kolterman et al. · 2005 [cited by applicant]
US 6903074B1 · Morgan et al. · 2005 [cited by applicant]
US 6956026B2 · Beeley et al. · 2005 [cited by applicant]
US 7223440B2 · Rickey et al. · 2007 [cited by applicant]
US 7235627B2 · Knudson et al. · 2007 [cited by applicant]
US 7238663B2 · DeFelippis et al. · 2007 [cited by applicant]
US 7297761B2 · Beeley et al. · 2007 [cited by applicant]
US 7456254B2 · Wright et al. · 2008 [cited by applicant]
US 7521423B2 · Young et al. · 2009 [cited by applicant]
US 7563871B2 · Wright et al. · 2009 [cited by applicant]
US 7612176B2 · Wright et al. · 2009 [cited by applicant]
US 7741269B2 · Young et al. · 2010 [cited by applicant]
US 8076288B2 · Levy et al. · 2011 [cited by applicant]
US 8114833B2 · Pedersen et al. · 2012 [cited by applicant]
US 8216180B2 · Tschirren et al. · 2012 [cited by applicant]
US 8268781B2 · Gotthardt et al. · 2012 [cited by applicant]
US 8299025B2 · Alessi et al. · 2012 [cited by applicant]
US 8329648B2 · Fineman et al. · 2012 [cited by applicant]
US 8431685B2 · Wright et al. · 2013 [cited by applicant]
US 8439864B2 · Galbraith et al. · 2013 [cited by applicant]
US 8445647B2 · Prickett et al. · 2013 [cited by applicant]
US 8461105B2 · Wright et al. · 2013 [cited by applicant]
US 8546326B2 · Joabsson et al. · 2013 [cited by applicant]
US 8846612B2 · Aprikian et al. · 2014 [cited by applicant]
US 8895033B2 · Houchin et al. · 2014 [cited by applicant]
US 8906851B2 · Fineman et al. · 2014 [cited by applicant]
US 8969293B2 · Imran · 2015 [cited by applicant]
US 9616108B2 · Stoffers et al. · 2017 [cited by applicant]
US 9821031B2 · Stoffers et al. · 2017 [cited by applicant]
US 10188702B2 · Stoffers et al. · 2019 [cited by applicant]
US 10639354B2 · McLaughlin et al. · 2020 [cited by applicant]
US 10653753B2 · Xiong · 2020 [cited by applicant]
US 10660937B2 · McLaughlin et al. · 2020 [cited by applicant]
US 10987407B2 · Stoffers et al. · 2021 [cited by applicant]
US 10993991B2 · McLaughlin et al. · 2021 [cited by applicant]
US 10993992B2 · McLaughlin et al. · 2021 [cited by applicant]
US 11020484B2 · Xiong et al. · 2021 [cited by applicant]
US 11116820B2 · Xiong · 2021 [cited by applicant]
US 11617782B2 · McLaughlin et al. · 2023 [cited by applicant]
US 11622995B2 · McLaughlin et al. · 2023 [cited by applicant]
US 11738086B2 · Xiong et al. · 2023 [cited by applicant]
US 12102663B2 · McLaughlin et al. · 2024 [cited by applicant]
US 12220444B2 · McLaughlin et al. · 2025 [cited by applicant]
US 20020107277A1 · Gronberg et al. · 2002 [cited by applicant]
US 20020123461A1 · Drucker et al. · 2002 [cited by applicant]
US 20040092443A1 · Fridkin et al. · 2004 [cited by applicant]
US 20040116331A1 · Seeley et al. · 2004 [cited by applicant]
US 20040142866A1 · Sun et al. · 2004 [cited by applicant]
US 20080269130A1 · Stoffers et al. · 2008 [cited by applicant]
US 20090028832A1 · Chung et al. · 2009 [cited by applicant]
US 20090105341A1 · Stanton · 2009 [cited by applicant]
US 20100029554A1 · Ghosh et al. · 2010 [cited by applicant]
US 20110124555A1 · Schmid · 2011 [cited by applicant]
US 20120178676A1 · Barrack et al. · 2012 [cited by applicant]
US 20130172250A1 · Fineman et al. · 2013 [cited by applicant]
US 20130195939A1 · Kidron · 2013 [cited by applicant]
US 20130252894A1 · Kuzma et al. · 2013 [cited by applicant]
US 20140256626A1 · Santi et al. · 2014 [cited by applicant]
US 20140309168A1 · Rosendahl · 2014 [cited by applicant]
US 20150005233A1 · DeFrees · 2015 [cited by applicant]
US 20150056285A1 · Houchin et al. · 2015 [cited by applicant]
US 20150057227A1 · Leung · 2015 [cited by applicant]
US 20150238568A1 · Fineman et al. · 2015 [cited by applicant]
US 20150258016A1 · Alessi et al. · 2015 [cited by applicant]
US 20150274800A1 · Schellenberger et al. · 2015 [cited by applicant]
US 20150368311A1 · Haack et al. · 2015 [cited by applicant]
US 20160185837A1 · Bednarek et al. · 2016 [cited by applicant]
US 20180050095A1 · Stoffers et al. · 2018 [cited by applicant]
US 20180117122A1 · McLaughlin et al. · 2018 [cited by applicant]
US 20180147261A1 · McLaughlin et al. · 2018 [cited by applicant]
US 20190060413A1 · Xiong · 2019 [cited by applicant]
US 20190336584A1 · Stoffers et al. · 2019 [cited by applicant]
US 20200069802A1 · Xiong et al. · 2020 [cited by applicant]
US 20200276271A1 · McLaughlin et al. · 2020 [cited by applicant]
US 20200276272A1 · McLaughlin et al. · 2020 [cited by applicant]
US 20200297819A1 · Xiong · 2020 [cited by applicant]
US 20210252110A1 · Stoffers et al. · 2021 [cited by applicant]
US 20210290731A1 · McLaughlin et al. · 2021 [cited by applicant]
US 20210315974A1 · McLaughlin et al. · 2021 [cited by applicant]
US 20210315995A1 · Xiong et al. · 2021 [cited by applicant]
US 20210338780A1 · Craig et al. · 2021 [cited by applicant]
US 20210369814A1 · Xiong · 2021 [cited by applicant]
US 20230346890A1 · McLaughlin et al. · 2023 [cited by applicant]
US 20240000894A1 · McLaughlin et al. · 2024 [cited by applicant]
US 20240058422A1 · DiMarchi et al. · 2024 [cited by applicant]
US 20240082361A1 · Stoffers et al. · 2024 [cited by applicant]
US 20240316156A1 · Xiong · 2024 [cited by applicant]
US 20250312420A1 · Stoffers et al. · 2025 [cited by applicant]
US 20260034221A1 · Xiong et al. · 2026 [cited by applicant]
US 20260048101A1 · Craig et al. · 2026 [cited by applicant]
CL 2017002911A1 · 2018 [cited by applicant]
CL 2017002913 · 2018 [cited by applicant]
EP 1609478 · 2005 [cited by applicant]
EP 1609479 · 2005 [cited by applicant]
JP 2002534450 · 2002 [cited by applicant]
JP 2004532262A · 2004 [cited by applicant]
JP 2013129673A · 2013 [cited by applicant]
JP 2015514090A · 2015 [cited by applicant]
WO 9325579 · 1993 [cited by applicant]
WO 2002081649 · 2002 [cited by applicant]
WO 2008085982 · 2008 [cited by applicant]
WO 2011109787 · 2011 [cited by applicant]
WO 2016191394 · 2016 [cited by applicant]
WO 2016191395 · 2016 [cited by applicant]
WO 2017152014A1 · 2017 [cited by applicant]
WO 2018094404 · 2018 [cited by applicant]
Sabi et al. Diabetes, Metabolic Syndrome and Obesity 2024:17 4439-4452. [cited by examiner]
[No Author], “Evaluation of the Effects of Avexitide on Nutritional Status in Patients with Severe Restriction of Oral Intake Following Upper Gastrointestinal Surgery,” Research Paper, Nov. 6, 2023, 8 pages. [cited by applicant]
Ackermann et al., “Managing congenital hyperinsulinism: improving outcomes with a multidisciplinary approach,” Research and Reports in Endocrine Disorders, Jul. 2015, 31:103-17. [cited by applicant]
Adzick et al., “Surgical treatment of congenital hyperinsulinism: Results from 500 pancreatectomies in neonates and children,” Journal of Pediatric Surgery, Jan. 2019, 54(1):27, 16 pages. [cited by applicant]
Agiostratidou et al., “Standardizing clinically meaningfuloutcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabe… [cited by applicant]
Aguilar-Bryan et al., “Cloning of the β cell high-affinity sulfonylurea receptor: a regulator of insulin secretion,” Science, Apr. 1995, 268(5209):423-6. [cited by applicant]
Amylyx, “A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants with Post-Bariatric Hypoglycemia,” In Approval, Oct. 7, 2024, 85 pages. [cited by applicant]
Amylyx, “A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants with Post-Bariatric Hypoglycemia,” Unversioned Draft, Sep. 26, 2024, 84… [cited by applicant]
Amylyx, “Avexitide: Novel GLP-1 Receptor Antagonist for the Potential Treatment of HyperinsulinemicHypoglycemia,” Jun. 27, 2024, Amylyx Exchange, 18 pages. [cited by applicant]
Aulinger et al., “Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade,” Diabetes, Mar. 2014, 63(3):1079-92. [cited by applicant]
Aung et al., “Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes,” Diabetologia, Sep. 2019, 62:1701-11. [cited by applicant]
Avatapalle et al., “Drug-induced hepatitis following use of octreotide for long-term treatment of congenital hyperinsulinism,” BMJ Case Reports, Jan. 2012, vol. 2012(30), 3 pages. [cited by applicant]
Beltrand et al., “Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism,” Diabetes Care, Feb. 2012, 35(2):198-203. [cited by applicant]
Brar et al., “Management and appropriate use of diazoxide in infants and children with hyperinsulinism,” The Journal of Clinical Endocrinology & Metabolism, Dec. 2020, 105(12):3750-61. [cited by applicant]
Care, “Glycemic targets: standards of medical care in diabetes—2019,” Diabetes Care, Jan. 2019, 42(Supplement 1):S61-70. [cited by applicant]
Chakraborty et al., “GI dysfunctions in diabetic gastroenteropathy, their relationships with symptoms, and effects of a GLP-1 antagonist,” The Journal of Clinical Endocrinology & Metabolism, Jun. 2019, 104(6):1967-77. [cited by applicant]
Chakraborty et al., “Relationship between symptoms during a gastric emptying study and intestinal chemosensitivity with daily symptoms,” Neurogastroenterology & Motility, Oct. 2019, 31(10):e13686, 9 pages. [cited by applicant]
clinicaltrials.gov, Accession No. NCT00835328, “Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia,” Feb. 2, 2009, 12 pages. [cited by applicant]
Craig et al., “PREVENT: a randomized, placebo-controlled crossover trial of avexitide for treatment of postbariatric hypoglycemia,” The Journal of Clinical Endocrinology & Metabolism, Aug. 2021, 106(8):e3235-48. [cited by applicant]
De León et al., “Mechanisms of disease: advances in diagnosis and treatment of hyperinsulinism in neonates,” Nature Clinical Practice Endocrinology & Metabolism, Jan. 2007, 3(1):57-68. [cited by applicant]
Deane et al., “Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia,” The Journal of Clinical Endocrinology & Metabolism, Jan. 2010, 95(1):215-21. [cited by applicant]
Demirbilek et al., “Diagnosis and treatment of hyperinsulinaemic hypoglycaemia and its implications for paediatric endocrinology,” International Journal of Pediatric Endocrinology, Dec. 2017, vol. 2017, 18 pages. [cited by applicant]
eigerbio.com, “About Post-Bariatric Hypoglycemia (PBH): PBH is a severe complication of bariatric and other gastrointestinal surgeries,” American Diabetes Association, 76th Scientific Sessions, Jun. 10-14, 2016; New Orl… [cited by applicant]
El Bekay et al., “Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes,” British journal of pharmacology, Jun. 2016, 173(11):1820-34. [cited by applicant]
Galcheva et al., “The genetic and molecular mechanisms of congenital hyperinsulinism,” Frontiers in Endocrinology, Feb. 2019, 10:111, 18 pages. [cited by applicant]
Gasbjerg et al., “GIP and GLP-1 receptor antagonism during a meal in healthy individuals,” The Journal of Clinical Endocrinology & Metabolism, Mar. 2020, 105(3):e725-38. [cited by applicant]
Gasbjerg et al., “Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals,” Diabetes, May 2019, 68(5):906-17. [cited by applicant]
Helleskov et al., “Both low blood glucose and insufficient treatment confer risk of neurodevelopmental impairment in congenital hyperinsulinism: a multinational cohort study,” Frontiers in Endocrinology, Jul. 2017, 8:15… [cited by applicant]
Helsted et al., “The role of endogenous GIP and GLP-1 in postprandial bone homeostasis,” Bone, Nov. 2020, 140:115553, 7 pages. [cited by applicant]
Herrera et al., “Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide,” The Journal of Clinical Endocrinology & Metabolism, Dec. 2018, 103(12):4365-72. [cited by applicant]
Jacobs et al., “Growth and development in patients operated on for islet cell dysplasia,” Journal of Pediatric Surgery, Dec. 1986, 21(12):1184-9. [cited by applicant]
Jiménez et al., “GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery,” Diabetes Care, Jul. 2013, 36(7):2062-9. [cited by applicant]
Jiménez et al., “GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes,” Diabetes, Oct. 2014, 63(10):3372-7. [cited by applicant]
Jørgensen et al., “Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes,” Sep. 2013, 62(9… [cited by applicant]
Kefurt et al., “Hypoglycemia after Roux-En-Y gastric bypass: detection rates of continuous glucose monitoring (CGM) versus mixed meal test,” Surgery for Obesity and Related Diseases, May 2015, 11(3):564-9. [cited by applicant]
Laje et al., “Necrotizing in neonates receiving octreotide for the management of congenital hyperinsulinism,” Pediatric Diabetes, Mar. 2010, 11(2):142-7. [cited by applicant]
Lee, et al. “OR20-5 28-Day Dosing with Avexitide Improves Hyperinsulinemic Hypoglycemia in Patients with Severe, Refractory Post-Bariatric Hypoglycemia: The PREVENT Study”, Journal of the Endocrine Society, vol. 3, Issu… [cited by applicant]
Leibowitz et al., “Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up,” The Journal of Clin… [cited by applicant]
Li et al., “A signaling role of glutamine in insulin secretion,” Journal of Biological Chemistry, Apr. 2004, 279(14):13393-401. [cited by applicant]
Lord et al., “High risk of diabetes and neurobehavioral deficits in individuals with surgically treated hyperinsulinism,” The Journal of Clinical Endocrinology & Metabolism, Nov. 2015, 100(11):4133-9. [cited by applicant]
Ludwig et al., “Glucose metabolism and neurological outcome in congenital hyperinsulinism,” Seminars in Pediatric Surgery, Feb. 2011, 20(1):45-9. [cited by applicant]
McMahon et al., “Octreotide use and safety in infants with hyperinsulinism,” Pharmacoepidemiology and Drug Safety, Jan. 2017, 26(1):26-31. [cited by applicant]
Meissner et al., “Long-term follow-up of 114 patients with congenital hyperinsulinism,” European Journal of Endocrinology, Jul. 2003, 149(1):43-51. [cited by applicant]
Melhorn et al., “Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans,” Appetite, Nov. 2014, 82:85-90. [cited by applicant]
Menni et al., “Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia,” Pediatrics, Mar. 2001, 107(3):476-9. [cited by applicant]
Meyer-Gerspach et al., “Endogenous GLP-1 alters postprandial functional connectivity between homeostatic and reward-related brain regions involved in regulation of appetite in healthy lean males: a pilotstudy,” Diabetes… [cited by applicant]
Mohnike et al., “Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon,” Hormone Research in Paediatrics, May 2008, 70(1):59-64. [cited by applicant]
Nauck et al., “Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and patients with type 2 diabetes using exendin [9-39] as a GLP-1 … [cited by applicant]
Ng C. et al, Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism, Br. J. Clin. Pharmacol. Mar. 2018; 84(3):520-532. [cited by applicant]
Nicolaus et al., “Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying,” The Journal of Clinical Endocrinology & Metabolism, Jan. 2011, 96(1):229-… [cited by applicant]
Ocampo-Garcia et al., “99mTc-exendin (9-39)/octreotide: biokinetics and radiation dosimetry in healthy individuals,” Nuclear Medicine Communications, Nov. 2017, 38(11):912-8. [cited by applicant]
Page et al., “Interaction of GLP-1 and ghrelin on glucose tolerance in healthy humans,” Diabetes, Oct. 2018, 67(10):1976-85. [cited by applicant]
Patterson et al., “A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1,” ACS Chemical Biology, Feb. 2011, 6(2):135-45. [cited by applicant]
Patterson et al., “A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1,” Supplemental Methods, ACS Chemical Biology, Feb. 2011, 20 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2017/020596, mailed on Sep. 13, 2018, 7 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International appln. No. PCT/US2017/062838, mailed on May 31, 2019, 6 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2022/034415, mailed on Dec. 14, 2023, 7 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Patent Appln. No. PCT/US2016/033836, mailed on Dec. 7, 2017, 12 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Patent appln. No. PCT/US2019/056278, mailed on Apr. 29, 2021 12 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International appln. No. PCT/US2008/000281, mailed on Jan. 8, 2008, 8 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International appln. No. PCT/US2017/020596, mailed on May 26, 2017, 9 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International appln. No. PCT/US2017/062838, mailed on Jan. 23, 2018, 8 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2022/034415, mailed on Sep. 9, 2022, 12 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International appn. No. PCT/US2016/033837, mailed on Aug. 18, 2016, , 8 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Patent appln. No. PCT/US2019/056278, mailed on Jan. 15, 2020, 16 pages. [cited by applicant]
Runge et al., “Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity,” British journal of pharmacology, Mar. 2003, 138(5):787-94. [cited by applicant]
Sah et al., “Gastric cancer surgery: Billroth I or Billroth II for distal gastrectomy?,” BMC Cancer, Dec. 2009, 9:428, 8 pages. [cited by applicant]
Salehi et al., “Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes,” Diabetes, Jun. 2010, 59(6):1330-7. [cited by applicant]
Sathananthan et al., “Direct effects of exendin-(9, 39) and GLP-1-(9, 36) amide on insulin action, β-cell function, and glucose metabolism in nondiabetic subjects,” Diabetes, Aug. 2013, 62(8):2752-6. [cited by applicant]
Schirra et al., “GLP-1 regulates gastroduodenal motility involving cholinergic pathways,” Neurogastroenterology & Motility, Jun. 2009, 21(6):609-e22. [cited by applicant]
Seino et al., “Physiological and pathophysiological roles of ATP-sensitive K+ channels,” Progress in Biophysics and Molecular Biology, Feb. 2003, 81(2):133-76. [cited by applicant]
Serre et al., “Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′, 5′-monophosphate levels and β-cell glucose competence,” Endoc… [cited by applicant]
Shah et al., “Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass,” Diabetes, Feb. 2014, 63(2):483-93. [cited by applicant]
Shah et al., “Contribution of endogenous glucagon-like peptide-1 to changes in glucose metabolism and islet function in people with type 2 diabetes four weeks after Roux-en-Y gastric bypass (RYGB),” Metabolism, Apr. 201… [cited by applicant]
Shah et al., “Insulin clearance after oral and intravenous glucose following gastric bypass and gastric banding weight loss,” Diabetes Care, Feb. 2019, 42(2):311-7. [cited by applicant]
Stanley, “Perspective on the genetics and diagnosis of congenital hyperinsulinism disorders,” The Journal of Clinical Endocrinology & Metabolism, Mar. 2016, 101(3):815-26. [cited by applicant]
Steinert et al., “Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men,” The American Journal of Clinical Nutrition, Aug. 2014, 100(2):514-23. [cited by applicant]
Steinkrauss et al., “Effects of hypoglycemia on developmental outcome in children with congenital hyperinsulinism,” Journal of Pediatric Nursing, Mar. 2005, 20(2):109-18. [cited by applicant]
Svane et al., “Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery,” American Journal of Physiology—Endocrinology and Metabolism, Apr. 2016, 310(7):E505-14. [cited by applicant]
Svane et al., “Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery,” International Journal of Obesity, Nov. 2016, 40(11):1699-706. [cited by applicant]
Ten Kulve et al., “Elevated postoperative endogenous GLP-1 levels mediate effects of Roux-en-Y gastric bypass on neural responsivity to food cues,” Diabetes Care, Nov. 2017, 40(11):1522-9. [cited by applicant]
Ten Kulve et al., “Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption,” Journal of Endocrinology, Apr. 2016, 229(1):1-2. [cited by applicant]
Ten Kulve et al., “Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes,” Diabetologia, Dec. 2015, 58(12):2688-98. [cited by applicant]
Vajravelu et al., “Continuous intragastric dextrose: a therapeutic option for refractory hypoglycemia in congenital hyperinsulinism.,” Hormone Research in Paediatrics, Aug. 2019, 91(1):62-8. [cited by applicant]
Van Bloemendaal et al., “GLP-1 receptor activation modulates appetite-and reward-related brain areas in humans,” Diabetes, Dec. 2014, 63(12):4186-96. [cited by applicant]
Van der Steen et al., “A multicenter experience with long-acting somatostatin analogues in patients with congenital hyperinsulinism,” Hormone Research in Paediatrics, Dec. 2018, 89(2):82-9. [cited by applicant]
Verouhis et al., “Remote ischemic conditioning protects against endothelial ischemia-reperfusion injury via a glucagon-like peptide-1 receptor-mediated mechanism in humans,” International Journal of Cardiology, Jan. 201… [cited by applicant]
Wald et al., “Glucagon therapy as a possible cause of erythema necrolyticum migrans in two neonates with persistent hyperinsulinaemic hypoglycaemia,” European Journal of Pediatrics, Nov. 2002, 161:600-3. [cited by applicant]
Witte et al., “Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion,” Scandinavian Journal of Gastroenterology, Apr. 2011, 46(4):428-35. [cited by applicant]
Woerle et al., “The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes,” Diabetes, Sep. 2012, 61(9):2349-58. [cited by applicant]
“Amidation”, The Free Dictionary, available at https://www.thefreedictionary.com/Amidation, retrieved online on Nov. 21, 2019, 3 pages. [cited by applicant]
Alexopoulos K., et al, “Design and Synthesis of Novel Biologically Active Thrombin Receptor Non-Peptide Mimetics Based on the Pharmacophoric Cluster Phe/Arg/NH2 of the Ser42-Phe-Leu-Leu-Arg46 Motif Sequence: Platelet Ag… [cited by applicant]
Andreasen, J.J., et al., “Secretion of Glucagon-Like Peptide-1 and Reactive Hypoglycemia after Partial Gastrectomy”. Digestion, 1994. 55(4): p. 221-228. [cited by applicant]
Andronati, S.A. et al., “Peptidomimetics—Antagonists of the Fibrinogen Receptors: Molecular Design, Structures, Properties and Therapeutic Applications.” Curr Med Chem 11(9): 1183-211, 2004. [cited by applicant]
Ashkenazi A., et al., “Immunoadhesins”. Int. Rev. Immunol., vol. 10, Issue 2-3, 1993, p. 219-227, DOI:10.3109/08830189309061697. [cited by applicant]
Bantle, J.P., et al., “Hyperinsulinemic Hypoglycemia Developing Late after Gastric Bypass”, Obes Surg. vol. 17, https://doi.org/10.1007/s11695-007-9102-6, May 2007, p. 592-595. [cited by applicant]
Botros, N., et al., “Effect of Carbohydrate Restriction in Patients with Hyperinsulinemic Hypoglycemia after Roux-en-Y Gastric Bypass”, Obes Surg. vol. 24, Issue 11, https://doi.org/10.1007/s11695-014-1319-6,Jun. 6, 201… [cited by applicant]
Breslin, M.J., et al, “Non-Peptide alphavbeta3 Antagonists. Part 6: Design and Synthesis of alphavbeta3 Antagonists Containing a Pyridone or Pyrazinone Central Scaffold”. Bioorg & Med Chem Lett vol. 13, Issue 10, Jun. 2… [cited by applicant]
Buchwald, H., et al., “Long term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis”, Surgery, DOI:https://doi.org/10.5555/uri:pii:0039… [cited by applicant]
C6EVG1, accessed Mar. 10, 2023 at URL: uniport.org/uniport/C6WG1, 5 pages (Year: 2023). [cited by applicant]
Calabria, A.C., et al., “Postoperative Surveillance and Detection of Postprandial Hypoglycemia after Fundoplasty in Children”, published in final edited form as J Pediatr. vol. 159, No. 4, doi:10/1016/j.jpeds.2011.03.04… [cited by applicant]
Calabria, A.C., et al., “Postprandial Hypoglycemia in Children after Gastric Surgery: clinical characterization and pathophysiology”, Horm Res Paediatr, vol. 85, No. 2, 2016, p. 140-146, DOI:10.1159/000442155. [cited by applicant]
Calabria, A.C., et al., “GLP-1 Receptor Antagonist Exendin-(9-39) Elevates Fasting Blood Glucose Levels In Congenital Hyperinsulinism Owing to Inactivating Mutations in the ATP-Sensitive K+ Channel” Diabetes, vol. 61, N… [cited by applicant]
Cancelas, J., et al., “Resistance of Succinic Acid Dimethyl Ester Insulinotropic Action to Exendin (9-39) Amide”, Hormone and Metabolic Research, vol. 34, No. 1, Feb. 1, 2002, pp. 13-15, DOI:10.1055/s-2002-19960. [cited by applicant]
Cancelas, J., et al., “Suppression by Exendin(9-39)amide of Glucagon-Like Peptide-1 Insulinotropic Action in Rats Infused with Dimethyl Ester of Succinic Acid”, Endocrine, vol. 15, Issue 3, Aug. 2001, p. 283-5, DOI:10.1… [cited by applicant]
Caudy, A.A., et al. “Fragile X-related protein and VIG associate with the RNA interference machinery”, Genes & Development, vol. 16, No. 19, 2002, p. 2491-2496, DOI:10.1101/gad.1025202. [cited by applicant]
Chen, T., et al., “Interspecies Modeling and Prediction of Human Exenatide Pharmacokinetics”, Pharm Res., vol. 30, No. 3, Mar. 2013, p. 751-760, DOI:10.1007/s11095-012-0917-z. [cited by applicant]
Cheon, H.G., et al., “High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains”, Proceedings of the National Academy of Science, vol. 91, No. … [cited by applicant]
Corywell, W., “Depressive Disorders”, Merck Manuals Professional Edition, retrieved on Jun. 11, 2019 from https://www.merckmanuals.com/professional/psychiatric-disorders/mood-disorders/depressive-disorders, p. 1-10. [cited by applicant]
Cosgrove, K.E., et al., “BPDZ 154 Activates Adenosine 5′-Triphosphate-Sensitive Potassium Channels: In Vitro Studies Using Rodent Insulin-Secreting Cells and Islets Isolated from Patients with Hyperinsulinism”, The Jour… [cited by applicant]
Craig, C.M., et al. “Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia”, Diabetologia, vol. 60, Issue 3, DOI:https://doi.org/10.1007/s00125-016-4179-x, Published in final edited form on Mar. 2017, p. 5… [cited by applicant]
Craig, C.M., et al., “Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia”, Diabetes, Obesity and Metabolism, vol. 20, Issue 2, DOI:https://doi.org/10.1111/dom.1307… [cited by applicant]
Craig, C.M., et al., “Subcutaneous exendin (9-39) effectively treats post-bariatric hypoglycemia,” American Diabetes Association, 76th Scientific Sessions, Jun. 10-14, 2016; New Orleans, LA; Retrieved from the Internet … [cited by applicant]
Cryer, P. E., et al., “Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline”, Journal of Clinical Endocrinology and Metabolism, vol. 94, Issue 3, Mar. 2009, p. 709-… [cited by applicant]
Davidson, M.B, et al., “Exenatide,” Nature Reviews Drug Discovery, vol. 4, DOI:10.1038/nrd1828, Sep. 2005, p. 713-714. [cited by applicant]
De Leon, D.D., “Effect of Exendin-(9-38) on Glycemic Control in Subjects With Congenital Hyperinsulinism”, U.S. National Library of Medicine, ClinicalTrials.gov, retrieved on Nov. 21, 2019 from https://www.clinicaltrial… [cited by applicant]
De Leon, D.D., et al. “Exendin-(9-39) Corrects Fasting Hypoglycemia in SUR-1 / Mice by Lowering cAMP in Pancreatic beta-cells and Inhibiting Insulin Secretion” Journal of Biological Chemistry, vol. 283, Issue 38, Sep. 1… [cited by applicant]
De Leon, D.D., et al. “Role of Endogenous Glucagon-Like Peptide-1 in Islet Regeneration After Partial Pancreatectomy”, Diabetes, vol. 52, Feb. 2003, p. 365-371, doi.org/10.2337/diabetes.52.2.365. [cited by applicant]
De Leon, D.D., et al., “Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia”, Best Practice & Research Clinical Endocrinology & Metabolism, vol. 27, Issue 6, Dec. 2013, p. 763-769, doi.org/10.101… [cited by applicant]
Deary, I.J., et al., “Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis”, Diabetologia, vol. 35, Issue 8, DOI:https://doi.org/10.1007/BF00401150, 1993, p. 771-777. [cited by applicant]
Drucker, D.J., et al. “Biologic actions and therapeutic potential of the proglucagon-derived peptides”, Nature Clinical Practice Endocrinology & Metabolism, vol. 1, No. 1, Nov. 2005, p. 22-31, DOI:10.1038/ncpendmet0017. [cited by applicant]
Dunne, M.J., et al. “Hyperinsulinism in Infancy: From Basic Science to Clinical Disease”, Physiological Reviews, vol. 84, No. 1, DOI:10.1152/physrev.00022.2003, Jan. 2004, p. 239-275. [cited by applicant]
Edwards, C.M., et al. “Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39”, Diabetes, vol. 48, No. 1, Jan. 1999, p. 86-93, doi.org… [cited by applicant]
Edwards, C.M., et al., “Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects”, Clin Sci (Lond), vol. 95, No. 6, Dec. 1, 1998, p. 719-724, doi.org/10.… [cited by applicant]
Eisenberg, D., et al., “ASMBS Position Statement on Postprandial Hyperinsulinemic Hypoglycemia after Bariatric Surgery”, Surgery for Obesity and Related Diseases, vol. 13, Issue 3, DOI:https://doi.org/10.1016/j.soard.20… [cited by applicant]
Eliasson, L., et al. “SUR1 Regulates PKA-independent cAMP-induced Granule Priming in Mouse Pancreatic B-Cells”, J. Gen. Physiol, vol. 121, No. 3, DOI:10.1085/jgp.20028707, Mar. 2003, p. 181-197. [cited by applicant]
Eng, J., et al. “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspectum Venom: Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas”, The Journal of … [cited by applicant]
Evan, G.I., et al., “Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product”, Molecular and Cellular Biology, vol. 5, No. 12, Dec. 1985, p. 3610-3616. [cited by applicant]
Field, J., et al., “Purification of a RAS-responsive Adenylyl Cyclase Complex from [cited by applicant]
Foster-Schubert, K.E., “Hypoglycemia complicating bariatric surgery: incidence and mechanisms,” Current Opinion Endocrinology, Diabetes, and Obesity. Apr. 2011; 18(2): 129-133. doi: 10.1097/MED.Ob013e32834449b9. [cited by applicant]
Fournet, J.C., et al., “Unbalanced Expression of 11p15 Imprinted Genes in Focal Forms of Congenital Hyperinsulinism”, The Amercian Journal of Pathology, vol. 158, No. 6, Jun. 2001, DOI:https://doi.org/10.1016/S0002-9440… [cited by applicant]
Franco, J.V., et al., “A Review of Studies Comparing Three Laparoscopic Procedures in Bariatric Surgery: Sleeve Gastrectomy, Roux-en-Y Gastric Bypass and Adjustable Gastric Banding,” Obes Surg, vol. 21, No. 9, DOI:10.10… [cited by applicant]
Gardiner, S., et al., “Mesenteric Vasoconstriction and Hindquarters Vasodilatation Accompany the Pressor Actions of Exendin-4 in Conscious Rats”, Journal of Pharmacology and Experimental Therapeutics, vol. 316, No. 2, F… [cited by applicant]
Gebhard, B., et al., “Postprandial GLP-1, Norepinephrine, and Reactive Hypoglycemia in Dumping Syndrome”, Digestive Diseases and Sciences, vol. 46, Issue 9, Sep. 2001, p. 1915-1923, doi.org/10.1023/A:1010635131228. [cited by applicant]
Goke, R. et al., “Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells” The Journal of Biological Chem… [cited by applicant]
Goldfine, A.B., et al., “Patients with Neuroglycopenia after Gastric Bypass Surgery Have Exaggerated Incretin and Insulin Secretory Responses to a Mixed Meal”, The Journal of Clinical Endocrinology & Metabolism, vol. 92… [cited by applicant]
Goodson, J.M., Chapter 6 “Dental Applications” In: Medical Applications of Controlled Release, 1984, vol. 2, p. 116-138. [cited by applicant]
Gough, S.C.L, “Liraglutide: from clinical trials to clinical practice,” Diabetes, Obesity and Metabolism, vol. 14, Issue 2, DOI:https://doi.org/10.1111/j.1463-1326.2012.01576.x, 2012, p. 33-40. [cited by applicant]
Gurman P, Chi A, Hood T, Reina M, Rosen Y, D'hers S, Elman N. “Prefilled devices for parenteral applications,” Expert Rev Med Devices. Mar. 2014;11(2):205-23. doi: 10.1586/17434440.2014.882227. Epub Jan. 30, 2014. PMID:… [cited by applicant]
Heber, D., et al., “Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society Clinical Practice Guideline”, J Clin Endocrinol Metab. vol. 95, Issue 11, DOI:10.1210/jc.2009-2128, No… [cited by applicant]
Heidaran, M.A., et al., “Beta PDGFR-IgG chimera demonstrates that human beta PDGFR Ig-like domains 1 to 3 are sufficient for high affinity PDGF BB binding”, The FASEB Journal, vol. 9, No. 1, Jan. 1, 1995, p. 140-145, do… [cited by applicant]
Hepburn, D.A., et al., “Symptoms of acute insulin-induced hypoglycaemia in humans with and without IDDM”, Diabetes Care, vol. 14, No. 11, DOI:https://doi.org/10.2337/diacare.14.11.949, Nov. 1991, p. 949-957. [cited by applicant]
Hofeldt, F.D., “Reactive hypoglycemia”, Endocrinology and Metabolism Clinics of North America, vol. 18, No. 1, Mar. 1989, p. 185-201. [cited by applicant]
Hopp, T.P., et al., “A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification”, Bio/Technology, vol. 6, No. 10, Oct. 1988, p. 1204-1210, DOI:10.1038/nbt1088-1204. [cited by applicant]
Hussain, K., et al., “Medications used in the treatment of hypoglycemia due to congenital hyperinsulinism of infancy (HI)”, Pediatric Endocrinology Reviews, vol. 2, Supplement 1, Nov. 2004, p. 163-167. [cited by applicant]
International Hypoglycaemia Study Group (IHSG), Amiel, S.A., et al., “Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: A joint position statement of the American Diabetes … [cited by applicant]
Jezek, J., et al., “Biopharmaceutical formulations for pre-filled delivery devices”, Expert opinion on drug delivery, vol. 10, Issue 6, (2013): 811-828, DOI:10.1517/17425247.2013.780023. [cited by applicant]
Kapoor, R.R., et al., “Advances in the diagnosis and management of hyperinsulininemic hypoglycemia,” Nature Clinical Practice Endocrinology & Metabolism, vol. 5, No. 2, DOI:https://doi.org/10.1038/ncpendmet1046, Feb. 20… [cited by applicant]
Kellogg, T.A., et al., “Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet”, Surgery for Obesity and Related Diseases, vol. 4, Issue 4, DOI:10.1016/j.soard.2008.0… [cited by applicant]
Kenny, C., “When Hypoclycemia is not obvious: diagnosing and treating under-recognized and undisclosed hypoglycemia”, Primary Care Diabetes, vol. 8, Issue 1, DOI:http://dx.doi.org/10.1016/j.pcd.2013.09.002, Apr. 1, 2014… [cited by applicant]
Kielgast, U., et al. “Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual B-Cell Function”, Diabetes, vol. 60, Issue 5, May 2011, p. 1599-1607, doi.org/10.2337/db… [cited by applicant]
Kim, S.H., et al., “Glucose-stimulated insulin secretion in gastric bypass patients with hypoglycemic syndrome: no evidence for inappropriate pancreatic beta-cell function”, Obesity Surgery, vol. 20, Issue 8, DOI:https:… [cited by applicant]
Kim, S.H., et al., “Plasma Glucose and Insulin Regulation Is Abnormal Following Gastric Bypass Surgery with or Without Neuroglycopenia,” Obesity Surgery, vol. 19, Jun. 2009, DOI: 10.1007/s11695-009-9893-8, p. 1550-1556. [cited by applicant]
Koh, T.H., et al., “Neonatal hypoglycaemia—the controversy regarding definition”, Archives of Disease in Childhood, vol. 63, No. 11, Nov. 1988, p. 1386-1388, DOI:10.1136/adc.63.11.1386. [cited by applicant]
Kulkarni, R.N., et al., “Use of Exendin (9-39) Amide to define the in-vivo and in-vitro roles of GLP-1 (7-36) Amide in the regulation of Insulin secretion”, Regulatory Peptides, vol. 57, No. 2, May 1995, p. 201. [cited by applicant]
Kumareswaran, K., et al. “Closed-loop Insulin Delivery: Towards Improved Diabetes Care”, Discovery Medicine, vol. 13, No. 63, Feb. 23, 2012, p. 159-170. [cited by applicant]
Laferrere, B., et al., “Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes”, The Journal of Clinical Endocrinology & Metabolism, vol. … [cited by applicant]
Langa, K.M., et al., “The Diagnosis and Management of Mild Cognitive Impairment: A Clinical Review”, JAMA, vol. 312, Issue 23, DOI:https://doi.org/10.1001/jama.2014.13806, Dec. 17, 2014, p. 2551-2561. [cited by applicant]
Langer, R., “New Methods of Drug Delivery”, Science, vol. 249, Issue 4976, DOI:10.1126/science.2218494, Sep. 28, 1990, p. 1527-1533. [cited by applicant]
Larochelle, W.J., et al., “Specific Receptor Detection by a Functional Keratinocyte Growth Factor-Immunoglobulin Chimera”, The Journal of Cell Biology, vol. 129, No. 2, Apr. 15, 1995, p. 357-366, doi.org/10.1083/jcb.129… [cited by applicant]
Larraufie, P., et al., “Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery”, Cell Reports, DOI:https://doi.org/10.1016/j.celrep.2019.01.047, vol. 26, Issue 6, Feb. 5, 2019, p. 1399-1408. [cited by applicant]
Lasaosa, M., et al. “A liquid chromatography-mass spectrometry assay for quantification of Exendin[9-39] in human plasma”, J Chromatogr B Analyt Technol Biomed Life Sci., Feb. 1, 2014, p. 186-191, DOI:10.1016/j.jchromb.… [cited by applicant]
Lev-Ran, A., et al., “The diagnosis of postprandial hypoglycemia”, Diabetes, vol. 30, Issue 12, DOI:10.2337/diab.30.12.996, Dec. 1981, p. 996-999. [cited by applicant]
Lutz-Freyermuth, C., et al., “Quantitative determination that one of two potential RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with high affinity to stem—loop I… [cited by applicant]
Mandal, A., “Defining Hypoglycemia”, News Medical: Life Sciences, retrieved on Nov. 20, 2019 from https://www.news-medical.net/health/Defining-Hypoglycemia.aspx, 3 pages. [cited by applicant]
Manning, S., et al. “GLP-1: A Mediator of the Beneficial Metabolic Effects of Bariatric Surgery?”, Physiology, vol. 30, Issue 1, DOI:https://doi.org/10.1152/physiol.00027.2014, Jan. 1, 2015, p. 50-62. [cited by applicant]
Martin, G.A., et al., “GAP domains responsible for ras p21-dependent inhibition of muscarinic atrial K+ channel currents”, Science, vol. 255, Issue 5041, Jan. 10, 1992, p. 192-194, DOI:10.1126/science.1553544. [cited by applicant]
Mclaughlin, T., et al. “Reversible Hyperinsulinemic Hypoglycemia after Gastric Bypass: A Consequence of Altered Nutrient Delivery”, The Journal of Clinical Endocrinology & Metabolism, vol. 95, Issue 4, Apr. 1, 2010, pp.… [cited by applicant]
Mechanick, J.I., et al., “Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical … [cited by applicant]
Meier et al., “Comment to: Patti ME, McMahon G, Mun EC et al. (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplas… [cited by applicant]
Meijeren, J.V., et al., “Evaluation of carbohydrate restriction as primary treatment for post-gastric bypass hypoglycemia”, Surgery for Obesity and Related Diseases, vol. 13, Issue 3, DOI:https://doi.org/10.1016/j.soard… [cited by applicant]
Miholic, J., et al. “Emptying of the Gastric Substitute, Glucagon-like peptide-1 (GLP-1), and Reactive Hypoglycemia After Total Gastrectomy”, Digestive Diseases and Sciences, vol. 36, No. 10, Oct. 1991, p. 1361-1370, do… [cited by applicant]
Moize, V.L., et al., “Nutritional pyramid for post-gastric bypass patients”, Obesity Surgery, vol. 20, Issue 8, DOI:10.1007/s11695-010-0160-9, 2010, p. 1133-1141. [cited by applicant]
Montrose-Rafizadeh, C. et al. “High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor”, The Journal of Biological Chemistry, vol. 272, Issue 34, DOI:10.1074/jbc.272.34.21201, Aug. 22, 1997, p. 21201… [cited by applicant]
Myers, H.R., “Why Does Blood Pressure Drop After a Meal?”, Livestrong.com, retrieved on Nov. 21, 2019, from http://www.livestrong.com/article/413792-postprandial-hypoglycemic-diet/, 2 pages. [cited by applicant]
Myint, K.S., et al., “Prolonged successful therapy for hyperinsulinaemic hypoglycaemia after gastric bypass: the pathophysiological role of GLP1 and its response to a somatostatin analogue”, European Journal of Endocrin… [cited by applicant]
Nabel, E.G., “Cardiovascular Disease”, The New England Journal Of Medicine, vol. 349, Issue 1, DOI:10.1056/NEJMra035098, Jul. 3, 2003, p. 60-72. [cited by applicant]
National Center for Biotechnology Information, “PubChem Compound Summary for CID 129012199, Exendin (9-39)”, Available from: https://pubchem.ncbi.nlm.nih.gov/compound/129012199. Accessed Sep. 26, 2020, pp. 1-36. [cited by applicant]
Naz, R.K, et al., “Novel human prostate-specific cDNA: molecular cloning, expression, and immunobiology of the recombinant protein”, Biochemical and Biophysical Research Communications, vol. 297, Issue 5, Oct. 11, 2002,… [cited by applicant]
Ng, D.D., et al. ‘Acarbose treatment of postprandial hypoglycemia in children after Nissen fundoplication’, The Journal of Pediatrics, vol. 139, Issue 6, DOI:https://doi.org/10.1067/mpd.2001.119169, Dec. 2001, p. 877-87… [cited by applicant]
Nielsen, P.E., “Peptide nucleic acids as therapeutic agents”, Current Opinion In Structural Biology, vol. 9, Issue 3, DOI: https://doi.org/10.1016/S0959-440X(99)80047-5, Jun. 1999, p. 353-357. [cited by applicant]
Paborsky, L.R., et al., “Mammalian cell transient expression of tissue factor for the production of antigen”, Protein Engineering, Design and Selection, vol. 3, Issue 6, May 1990, p. 547-553, doi.org/10.1093/protein/3.6… [cited by applicant]
Pai, M. P., “Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults”, Pharmacotherapy, vol. 32, Issue 9 (2012): 856-868, DOI:10.1002/j.1875-9114.2012.01108.x. [cited by applicant]
Palladino, A.A., et al., “Hyperinsulinism in Infancy and Childhood: When an Insulin Level is Not Always Enough”, Clinical Chemistry, vol. 54, Issue 2, DOI:10.1373/clinchem.2007.098988, Jan. 2008, p. 256-263. [cited by applicant]
Palladino, A.A., et al., “Increased Glucagon-Like Peptide-1 secretion and Postprandial Hypoglycemia in Children after Nissen Fundoplication”, The Journal Of Clinical Endocrinology & Metabolism, vol. 94, Issue 1, DOI:10.… [cited by applicant]
Patti, M., et al., “Hypoglycemia after Gastric Bypass: The Dark Side of GLP-1”, Gastroentrology, vol. 146, Issue 3, DOI:10.1053/j.gastro.2014.01.038, Mar. 2014, p. 605-608. [cited by applicant]
Patti, M.E., et al., “Severe hypoglycemia postgastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia”, Diabetologia, vol. 48, Issue 11 (2005) p. 22… [cited by applicant]
Pramanick, S., et al., “Excipient Selection In Parenteral Formulation Development”, Pharma Times, vol. 45, No. 3, Mar. 2013, p. 65-77. [cited by applicant]
Salehi, M., et al., “Blockade of Glucagon-like Peptide 1 Receptor Corrects Postprandial Hypoglycemia After Gastric Bypass”, Gastroenterology, vol. 146, Issue 3, Mar. 2014, p. 669-680, doi.org/10.1053/j.gastro.2013.11.04… [cited by applicant]
Salehi, M., et al., “Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1-Stimulated Postprandial Insulin Secretion in Humans”, Diabetes, vol. 60, Issue 9, Sep. 2011, p. 2308-2314, doi.org/10.2337/db11-0203. [cited by applicant]
Saudek, C.D., et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery”, The New England Journal Of Medicine, vol. 321, No. 9, DOI: 10.1056/NEJM198908313210904, Aug. 31, 1989, … [cited by applicant]
Schirra, J., et al., “Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans”, Gut, vol. 55, Issue 2, Feb. 2006, p. 243-251, DOI:10.1136/gut.2004.059741. [cited by applicant]
Schirra, J., et al., “Exendin(9-39)amide Is an Antagonist of Glucagon-like Peptide-1(7-36)amide in Humans”, The Journal of Clinical Investigation, vol. 101, No. 7, Apr. 1, 1998, p. 1421-1430, doi.org/10.1172/JCI1349. [cited by applicant]
Scroochi, L.A., et al., “Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene”, Nature Medicine, vol. 2, No. 11, Nov. 1, 1996, p. 1254-1258, doi.org/10.1038/nm… [cited by applicant]
Seaquist, E.R., et al., “Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society”, Diabetes Care, vol. 36, Issue 5, DOI:https://doi.org/10.2337/dc12-2480 , May 2… [cited by applicant]
Sefton, M.V., “Implantable Pumps” Critical Reviews in Biomedical Engineering, vol. 14, Issue 3 , Dec. 1986, p. 201-240. [cited by applicant]
Seghers, V., et al. “Sur 1 Knockout Mice. A Model for KATP Channel-Independent Regulation of Insulin Secretion”, The Journal of Biological Chemistry, vol. 275, No. 13, DOI:10.1074/jbc.275.13.9270, Mar. 31, 2000, p. 9270… [cited by applicant]
Service, F.J., et al., “Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability”, Diabetes, vol. 19, Issue 9, DOI:https://doi.org/10.2337/diab.19.9.644, Sep. 1970, p. 644-655. [cited by applicant]
Service, G.J., et al., “Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery”, The New England Journal Of Medicine, vol. 353, Issue 3, Jul. 21, 2005, p. 249-254, DOI:10.1056/NEJMoa043690. [cited by applicant]
SIM—Results of the Alignment of 2 Protein Sequences—Sequence alignment of instant SEQ ID No. 1 and instant SEQ ID No. 5 (retrieved from https://web.expasy.org/cgi-bin/sim/sim.pl?prot on May 11, 2022, 3 pages) (Year: 202… [cited by applicant]
Skinner, R.H., et al., “Use of the Glu—Glu—Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins”, The Journal of Biological Chemistry, vol. 266, No. 2… [cited by applicant]
Song, J., et al., “NMR for the design of functional mimetics of protein-protein interactions: one key is in the building of bridges”, Biochemistry and Cell Biology, vol. 76, Issue 2-3, 1998, p. 177-188, DOI:10.1139/bcb-… [cited by applicant]
Stanley, C.A., et al., “Editorial: Advances in Diagnosis and Treatment of Hyperinsulinism in Infants and Children”, The Journal of Clinical Endocrinology & Metabolism, vol. 87, Issue 11, Nov. 2002, p. 4857-4859, DOI:10.… [cited by applicant]
Suhl, E., et al., “Medical nutrition therapy for post-bariatric hypoglycemia: practical insights”, Surgery for Obesity and Related Diseases, vol. 13, Issue 5, DOI:10.1016/j.soard.2017.01.025, May 2017, p. 888-896. [cited by applicant]
Tack, J., et al., “Pathophysiology, diagnosis and management of postoperative dumping syndrome”, Nature Reviews Gastroenterology & Hepatology, vol. 6, Issue 10, DOI:https://doi.org/10.1038/nrgastro.2009.148, Sep. 1, 200… [cited by applicant]
Tan, M.J., et al., “Repeat subcutaneous dosing of exendin 9-39 reduces hyperinsulinemic hypoglycemia and neuroglycopenic symptoms in patients with post-bariatric hypoglycemia”, Poster presentation at the American Diabet… [cited by applicant]
Thanthan, S., et al., “Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle”, Domestic Animal Endocrinology, vol. 42, Issue 3, DOI:https://doi.org/10.1016/j.domaniend.2011.11.0… [cited by applicant]
Todd, J.F., et al., “A tumor that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycemia and diabetes”, The Lancet, vol. 361, Issue 9353, Jan. 18, 2003, p. 228-230, doi.org/10.1016/S01… [cited by applicant]
Toft-Nielsen, M., et al., “Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia”, Diabetologia, vol. 41, Issue 10, 1998, p. 1180-1186, doi.org/10.1007/s001250051049. [cited by applicant]
Toft-Nielsen, M.-B., et al. , “Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes”, The Journal of Clinical Endocrinology & Metabolism, vol. 86, Issue 8, Aug. 1, 2001, p. 3853-3860, doi.org/… [cited by applicant]
Traina, A.N., et al., “Primer on Pramlintide, an Amylin Analog”, The Diabetes Educator, vol. 37, Issue 3, DOI:10.1177/0145721711403011, May/Jun. 2011, p. 426-431. [cited by applicant]
Vilsboll T., et al., No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose Diabet Medicine, vol. 18, Issue 2, Dec. 20, 2001, p. 144-149, doi.org/10.1046… [cited by applicant]
Vogt, A., et al., “A Non-peptide Mimetic of Ras-CAAX: selective Inhibition of Farnesyltransferase and Ras Processing”, The Journal of Biological Chemistry, vol. 270, No. 2, Issue of Jan. 13, 1995, pp. 660-664, doi.org/1… [cited by applicant]
Webb, M., et al., “Growth restriction and exendin 4 promote endocrine expression in cultured islet cells derived from patients with persistent hyperinsulinemic hypoglycemia of infancy (PHHI)”, Endocrine Research, vol. 3… [cited by applicant]
Williard, F.S., et al., “Small Molecule Allosteric Modulation of the Glucagon-Like Peptide-1 Receptor Enhances the Insulinotropic Effect of Oxyntomodulin”, Molecular Pharmacology, vol. 82, Issue 6, DOI:https://doi.org/1… [cited by applicant]
AU Notice of Acceptance in Australian Appln. No. 2022202506, mailed on May 21, 2025, 3 pages. [cited by applicant]
AU Notice of Acceptance in Australian Appln. No. 2023237119, mailed on Mar. 28, 2025, 3 pages. [cited by applicant]
AU Notice of Acceptance in Australian Appln. No. AU2022201973, May 6, 2025, 3 pages. [cited by applicant]
AU Office Action in Australian Appln. No. 2017361539, mailed on Oct. 28, 2022, 3 pages. [cited by applicant]
AU Office Action in Australian Appln. No. 2019359807, mailed on Jul. 23, 2024, 4 pages. [cited by applicant]
AU Office Action in Australian Appln. No. 2023237119, mailed on Aug. 15, 2024, 3 pages. [cited by applicant]
Barnett, “Exenatide,” Drugs of Today (Barcelona, Spain: 1998), Sep. 2005, 41(9):563-78. [cited by applicant]
Borner et al., “Brainstem GLP-1 signalling contributes to cancer anorexia-cachexia syndrome in the rat,” Neuropharmacologym, Mar. 2018, 131:282, 32 pages. [cited by applicant]
BR Office Action in Brazilian Application No. 112017025000-4, mailed on Mar. 13, 2025, 14 pages (with English translation). [cited by applicant]
BR Office Action in Brazilian Appln. No. 112017024997-9, mailed on Aug. 26, 2025, 12 pages (with English translation). [cited by applicant]
BR Office Action in Brazilian Appln. No. 112017024997-9, mailed on Mar. 13, 2025, 15 pages (with English translation). [cited by applicant]
BR Office Action in Brazilian Appln. No. 112017025000-4, mailed on Aug. 26, 2025, 12 pages (with English translation). [cited by applicant]
BR Office Action in Brazilian Appln. No. 112019010236-1, mailed on Dec. 24, 2024, 7 pages. [cited by applicant]
BR Office Action in Brazilian Appln. No. 112019010236-1, mailed on May 18, 2021, 5 pages (with English translation). [cited by applicant]
Brubaker et al., “Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors,” Receptors and Channels, Jan. 2002, 8(3-4):179-88. [cited by applicant]
CA Office Action for Canadian Application No. 3,024,358 mailed Jun. 6, 2022, 4 pages. [cited by applicant]
CA Office Action in Canadian Appln. No. 3043899, mailed on Sep. 12, 2023, 8 pages. [cited by applicant]
CL Office Action in Chilean Appln. No. 00892-2021, mailed on Oct. 20, 2022, 32 pages (with English translation). [cited by applicant]
CL Office Action in Chilean Appln. No. 2019-001366, mailed on Apr. 7, 2021, 27 pages (with English translation). [cited by applicant]
CL Office Action in Chilean Appln. No. 2019-001366, mailed on Jan. 19, 2024, 4 pages (with English translation). [cited by applicant]
CL Office Action in Chilean Appln. No. 2019-001366, mailed on Oct. 4, 2021, 30 pages (with English translation). [cited by applicant]
CL Office Action in Chilean Appln. No. 2019-01366, mailed on Aug. 6, 2025, 33 pages (with English translation). [cited by applicant]
CL Office Action in Chilean Appln. No. 2019-01366, mailed on Sep. 15, 2025, 13 pages (with English translation). [cited by applicant]
CL Office Action in Chilean Appln. No. 2021-00892, mailed on Oct. 22, 2025, 5 pages (with English translation). [cited by applicant]
CN Office Action in Chinese Appln. No. 201780078743.2, mailed on May 24, 2021, 10 pages (with English translation). [cited by applicant]
CN Office Action in Chinese Appln. No. 201780078743.2, mailed on May 7, 2022, 7 pages (with English translation). [cited by applicant]
CN Office Action in Chinese Appln. No. 201780078743.2, mailed on Nov. 26, 2021, 10 pages (with English translation). [cited by applicant]
CN Office Action in Chinese Appln. No. 201980068180.8, mailed on Apr. 23, 2025, 9 pages (with English translation). [cited by applicant]
CN Office Action in Chinese Appln. No. 201980068180.8, mailed on Dec. 7, 2023, 13 pages (with English translation). [cited by applicant]
CN Office Action in Chinese Appln. No. 201980068180.8, mailed on Jul. 25, 2024, 9 pages (with English translation). [cited by applicant]
Dailey et al., “Glucagon-like peptide 1 and appetite,” Trends in Endocrinology & Metabolism, Feb. 2013, 24(2):85, 13 pages. [cited by applicant]
Degn et al., “Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia,” Diabetes, Sep. 2004, 53(9):2397-403. [cited by applicant]
EP European Search Report for European Appln. No. 22156122.8, mailed on Jun. 30, 2022, 9 pages. [cited by applicant]
EP Extended European Search Report in European appln. No. 16800620.3, mailed on Nov. 28, 2018, 5 pages. [cited by applicant]
EP Extended European Search Report in European appln. No. 08713063.9, mailed Aug. 30, 2011, 5 pages. [cited by applicant]
EP Extended European Search Report in European appln. No. 14171762.9, mailed on Dec. 1, 2014, 6 pages. [cited by applicant]
EP Extended European Search Report in European appln. No. 16800621.1, mailed on Mar. 9, 2018, 4 pages. [cited by applicant]
EP Extended European Search Report in European Appln. No. 17871296.4, mailed on Jul. 7, 2020, 9 pages. [cited by applicant]
EP Extended European Search Report in European appln. No. 18201976.0, mailed on Jan. 21, 2019, 6 pages. [cited by applicant]
EP Extended European Search Report in European Appln. No. 19873113.5, mailed on Jun. 15, 2022, 9 pages. [cited by applicant]
EP Extended European Search Report in European Appln. No. 23151717.8, mailed on Sep. 22, 2023, 22 pages. [cited by applicant]
EP Extended European Search Report in European Appln. No. 24222303.0, mailed on Jun. 27, 2025, 6 pages. [cited by applicant]
EP Office Action in European appln. No. 16800621.1, mailed on Feb. 22, 2019, 3 pages. [cited by applicant]
EP Office Action in European Appln. No. 17871296.4, mailed on Feb. 17, 2022, 8 pages. [cited by applicant]
EP Office Action in European Appln. No. 21176474.1, mailed on Sep. 15, 2025, 7 pages. [cited by applicant]
EP Office Action in European Appln. No. 22744570.7, mailed on Aug. 27, 2025, 6 pages. [cited by applicant]
EP Office Action in European Appln. No. 23151717.8, mailed on Sep. 9, 2025, 6 pages. [cited by applicant]
EP Office Action in European Appln. No. EP21194982.1, mailed on May 14, 2025, 4 pages. [cited by applicant]
Holst, “The Physiology of Glucagon-like Peptide 1,” Physiological Reviews, Oct. 2007, 87:1409-1439. [cited by applicant]
Hong et al., “Herbal medicine for dumping syndrome: a systematic review and meta-analysis,” Integrative Cancer Therapies, Sep. 2019, 18, 12 pages. [cited by applicant]
IL Office Action in Israeli Appln. No. 266568, mailed on Oct. 14, 2021, 9 pages (with English translation). [cited by applicant]
IL Office Action in Israeli Appln. No. 266568, mailed on Sep. 18, 2022, 9 pages (with English translation). [cited by applicant]
IL Office Action in Israeli Appln. No. 282059, mailed on Nov. 29, 2023, 4 pages (English translation). [cited by applicant]
IL Office Action in Israeli Appln. No. 314504, mailed on Feb. 5, 2025, 4 pages. [cited by applicant]
IN Office Action in Indian Appln. No. 201917020944, mailed on Aug. 9, 2023, 3 pages. [cited by applicant]
IN Office Action in Indian Appln. No. 201917020944, mailed on Feb. 15, 2021, 6 pages. [cited by applicant]
JP Office Action in Japanese Appln. No. 2019-527188, mailed on Apr. 5, 2022, 4 pages (with English translation). [cited by applicant]
JP Office Action in Japanese Appln. No. 2019-527188, mailed on Feb. 27, 2024, 4 pages (with English translation). [cited by applicant]
JP Office Action in Japanese Appln. No. 2019-527188, mailed on Sep. 14, 2021, 6 pages (with English translation). [cited by applicant]
JP Office Action in Japanese Appln. No. 2021-545283, mailed on Oct. 3, 2023, 4 pages (with English translation). [cited by applicant]
JP Office Action in Japanese Appln. No. 2022-123899, mailed on Jul. 11, 2023, 4 pages (with English translation). [cited by applicant]
JP Office Action in Japanese Appln. No. 2022-123899, mailed on Mar. 5, 2024, 2 pages (with English translation). [cited by applicant]
JP Office Action in Japanese Appln. No. 2024-100740, mailed on Aug. 5, 2025, 9 pages (with English translation). [cited by applicant]
Kinzig et al., “The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness,” Journal of Neuroscience, Dec. 2002, 22(23):10470-6. [cited by applicant]
Kittah et al., “A pilot study examining the effects of GLP-1 receptor blockade using exendin-(9, 39) on gastric emptying and caloric intake in subjects with and without bariatric surgery, Metabolic Syndrome and Related … [cited by applicant]
Landi et al., “Anorexia, physical function, and incident disability among the frail elderly population: results from the ilSIRENTE study,” Journal of the American Medical Directors Association, May 2010, 11(4):268-74. [cited by applicant]
Martin et al., “Modulation of taste sensitivity by GLP-1 signaling in taste buds,” Annals of the New York Academy of Sciences, Jul. 2009, 1170(1):98-101. [cited by applicant]